FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights

FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights

Teresa Krakauer Department of Immunology, Molecular Translational Sciences Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA Abstract: Immunostimulating staphylococcal enterotoxin B (SEB) and related superantigenic toxins cause...

Full description

Bibliographic Details
Main Author: Krakauer T
Format: Article
Language:English
Published: Dove Medical Press 2017-05-01
Series:ImmunoTargets and Therapy
Subjects:
Immunosuppressant
superantigen
toxic shock
NFκB
mTORC1
Online Access:https://www.dovepress.com/fda-approved-immunosuppressants-targeting-staphylococcal-superantigens-peer-reviewed-article-ITT

Internet

https://www.dovepress.com/fda-approved-immunosuppressants-targeting-staphylococcal-superantigens-peer-reviewed-article-ITT

Similar Items